Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Neoplasm Metastasis 1Leukemia, Myeloid 1Graft vs Host Disease 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

fludarabine 9Cytarabine 9venetoclax 5fludarabine phosphate 5Cyclophosphamide 5Busulfan 5thymoglobulin 4Tacrolimus 4Sirolimus 4Mycophenolic Acid 4Methotrexate 4Azacitidine 4aldesleukin 3Whole-Body Irradiation 3Interleukin-2 3Antilymphocyte Serum 3asciminib 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Dasatinib 2Cyclosporine 2Bone Marrow Transplantation 2Blood Specimen Collection 2Behavior Therapy 2zileuton 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid × interferon gamma-1b × Clear all
NCT04628338 2025-04-29

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

University of Pittsburgh

Phase EARLY_PHASE1 Completed
8 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡